Michigan State University recognizes COVID-19 vaccines not approved for use in the United States with lower documented efficacy than natural immunity, according to a federal lawsuit.
It’s the second filed by the New Civil Liberties Alliance (NCLA) against a public institution of higher education for refusing to exempt recovered individuals from a vaccine mandate.
Unlike its lawsuit against Virginia’s George Mason University, which NCLA withdrew Aug. 20 after GMU granted its client a medical exemption, the civil liberties group is seeking class-action status for the MSU suit. The Food and Drug Administration has also since approved a COVID-19 vaccine on a non-emergency basis.
Pfizer’s Comirnaty vaccine is “legally distinguishable” from the drugmaker’s BioNTech vaccine, which remains under emergency use authorization (EUA), NCLA told the court.
The former “is not widely available in the United States,” meaning MSU is still “essentially” forcing recovered employees including lead plaintiff Jeanna Morris to take either EUA vaccines or “worse yet” domestically unapproved vaccines recognized by the World Health Organization (WHO).
This explicitly violates the federal statutory framework for EUA vaccines, which requires the “free and informed consent of individuals” taking them, as well as the Ninth and Fourteenth Amendment rights of employees, according to the suit.
While MSU offers religious and medical exemptions, the former requires an intensive inquiry into a person’s beliefs and practices, and the latter is only granted for CDC-recognized contraindications.https://df759a9abc0ac0952a2b334d9beec5f9.safeframe.googlesyndication.com/safeframe/1-0-38/html/container.html
Morris is seeking a preliminary injunction against the vaccine mandate on the basis that MSU has required all employees — including fully remote workers such as her — to take at least the first of a two-dose vaccine by Aug. 31 or face discipline, including termination.
The docket shows the case was just assigned a judge Aug. 30, raising doubts about whether she can meet that deadline. Morris blames MSU for not providing an “early-peek, truncated version” of the mandate until a month before, and claims “earlier versions contained less information” about the extent of the requirement.
‘Less prone to evasion by the variants’
The evidence for the robustness of natural immunity relative to vaccine-induced immunity continues to grow.
A large Israeli study awaiting peer review concluded that “natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant” of COVID-19, which is dominant in Israel, compared to the two-dose BioNTech vaccine. (Recovered people who only took the first dose had improved protection, however.)
Researchers not involved in the study warned Science and MedPage Today that people shouldn’t seek out infections because COVID-19 is still dangerous to some groups.
A peer-reviewed paper in the forthcoming edition of the Journal of Immunology concluded that a “typical case of mild COVID-19” results in “long-lived, self-renewing memory” of the so-called CD8-positive T-cells that fight off the novel coronavirus.
The paper said these T-cells are “less prone to evasion by the variants of concern emerging worldwide” relative to antibodies, according to excerpts posted by the president of Concerned Ontario Doctors. If they show the same dynamics as T cells from SARS-CoV-1, the early 2000s predecessor to COVID-19, these T-cells “can persist for up to 17 years, and perhaps even longer.”
The MSU lawsuit cites the new Israeli research as well as earlier data from Israel, a highly vaccinated country, and other research on T- and B-cell longevity. Natural immunity was also deemed to have a similar “protective effect” as a two-dose vaccine, based on a review of research presented on a July “clinician call” hosted by the CDC and Infectious Diseases Society of America. (The lawsuit lists the wrong date for the call.)Image
Presentation from CDC-IDSA COVID-19 Clinician Call, July 17 2021Presentation from CDC-IDSA COVID-19 Clinician Call, July 17 2021
“Given that there is currently more data on the durability of naturally acquired immunity than there is for vaccine immunity, researchers rely on the expected durability of naturally acquired immunity to predict that of vaccine immunity,” the suit says.
NCLA lawyer Jenin Younes told Just the News her group updated its review of natural immunity studies since the GMU lawsuit. The Israeli study was published just two days before NCLA’s MSU suit.
Both university lawsuits share much in common, including declarations by Harvard Medical School’s Martin Kulldorff and Stanford Med’s Jay Bhattacharya, the coauthors of the Great Barrington Declaration, on the efficacy of natural immunity.
Immunologist Hooman Noorchashm, a former University of Pennsylvania and Harvard Med professor, also reviewed Morris’s self-reported symptoms and confirmed her prior infection through a “full COVID-19 serological screening” Aug. 20.
Unlike his review for GMU professor Todd Zywicki, Noorchasm doesn’t mention a specific medical condition for which vaccination would pose a threat to Morris, a 37-year-old woman. He simply states that MSU’s vaccine mandate would expose her to “an elevated risk of adverse effects, including serious ones,” based on current medical literature.
“Notably many of these studies focused on the adverse effects of receiving just the first dose of a vaccine,” Noorchasm said. “They do not examine the frequency or severity of receiving a second dose of a vaccine,” as required by MSU’s mandate in the case of mRNA vaccines.
The doctors emphasize that none of the vaccines approved for American use was tested on recovered COVID patients in clinical trials.
They also responded to a CDC study that purported to find greater protection from vaccine-induced immunity than from natural. The doctors said the increased antibody levels in vaccinated patients do not equal greater protection “against symptomatic disease, hospitalizations or deaths,” and the study did not include never-infected vaccinated patients.
But the heart of the lawsuit is the university’s acceptance of vaccines not authorized under any basis in the United States.
The WHO approved China’s Sinovac despite finding that it “prevented symptomatic disease in just 51% of those who received it,” and the vaccine has underperformed against the Delta variant. Several countries have stopped using the WHO-approved Sinopharm after “real-world experience” cast doubt on its purported 78% efficacy rate.
Even Johnson & Johnson’s one-shot vaccine, approved under an EUA, only has a 66.3% efficacy rate as measured in clinical trials, “far below” that measured for natural immunity.
Morris is “far less likely to contract or spread the virus than those in the MSU community who have been immunized with these inferior vaccines … and thus pose a greater danger” to the community, yet only recovered MSU employees are in danger of losing their jobs, the injunction motion says.
MSU didn’t respond to a query seeking its explanation of the scientific distinction between natural and vaccine-induced immunity, and why it accepts vaccines with lower documented efficacy rates than that provided by natural immunity.